MedTrace Logo

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

NCT00525161 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2015-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the clinical response rate to sorafenib when added to existing endocrine therapy in patients with advanced breast cancer.

Conditions

Interventions

DRUG

sorafenib

400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Suleiman Massarweh

    lead OTHER

Principal Investigators

  • Suleiman Massarweh, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2013-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525161 on ClinicalTrials.gov